Werida Rehab H, El-Sherif Salima, Shoshan Rania, Khedr Naglaa F
Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Damanhour, 22514, P.O, Egypt.
Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
BMC Health Serv Res. 2025 Mar 27;25(1):441. doi: 10.1186/s12913-025-12483-5.
The well-known anti-seizure medication, sodium valproate, is used to treat epilepsy, bipolar disorder, and other mental health conditions.
This study aimed to determine how pharmacist counseling intervention affected the prescribing patterns and usage of sodium valproate in patients with neurological diseases.
Patient prescriptions were analyzed in a quasi-experimental pretest-posttest design research, at baseline and after three months of pharmacy educational intervention. Medical history, drug-drug interactions, antipsychotic combinations, medication errors, and dosages were among the information gathered.
The reviewed prescriptions observed trend towards antipsychotic combination, 15 (2.5%) prescriptions had five medications, while 18 (3%) contained four, 169 (28.2%) containing three, 329 (54.8%) containing two, and 69 (11.5%) containing one, antipsychotic. Of the reviewed prescriptions, 6% had possible drug-drug interactions. However, following a 3-month pharmacy educational intervention, the tendency toward antipsychotic combination decreased significantly to 262 (52%) with prescriptions for 2 antipsychotics and 163 (32.3%) with 3 antipsychotics. Likewise, the decreases in medication errors related to frequency and dosage were 8 (1.6%) vs. 29 (4.8%) and 6 (1.2%) vs. 35 (5.8%), compared to baseline respectively. Additionally, medication adherence was raised significantly (p < 0.000) from 50 (8.3%) to 338 (67.1%) after the intervention.
More precise regulations should be placed on sodium valproate prescription patterns and usage, throughout implemented pharmacist initiative in patients counselling, provision of health education and therapeutic monitoring to improve health-related quality of life.
This study was registered on clinicaltrial.gov with an identification code NCT05830981. https://classic.
gov/ct2/show/NCT05830981 (First Posted: April 26, 2023).
著名的抗癫痫药物丙戊酸钠用于治疗癫痫、双相情感障碍和其他心理健康状况。
本研究旨在确定药师咨询干预如何影响神经疾病患者丙戊酸钠的处方模式和使用情况。
在一项准实验性的前测-后测设计研究中，分析患者在基线时和经过三个月药学教育干预后的处方。收集的信息包括病史、药物相互作用、抗精神病药物联合使用情况、用药错误和剂量等。
审查的处方呈现出抗精神病药物联合使用的趋势，15份（2.5%）处方有五种药物，18份（3%）含有四种，169份（28.2%）含有三种，329份（54.8%）含有两种，69份（11.5%）含有一种抗精神病药物。在审查的处方中，6%存在可能的药物相互作用。然而，经过三个月的药学教育干预后，抗精神病药物联合使用的趋势显著下降，使用两种抗精神病药物的处方降至262份（52%），使用三种抗精神病药物的处方降至163份（32.3%）。同样，与频率和剂量相关的用药错误分别从基线时的8份（1.6%）降至29份（4.8%），6份（1.2%）降至35份（5.8%）。此外，干预后用药依从性从50份（8.3%）显著提高到338份（67.1%）（p < 0.000）。
应通过实施药师在患者咨询、提供健康教育和治疗监测方面的举措，对丙戊酸钠的处方模式和使用进行更精确的规范，以提高与健康相关的生活质量。
本研究在clinicaltrial.gov上注册，识别码为NCT05830981。https://classic.clinicaltrials.gov/ct2/show/NCT0583098
